Jonathan P Moorman1,2, Matthew R Krolikowski3, Stephanie M Mathis4,5, Robert P Pack4,5. 1. Center of Excellence in Inflammation, Infectious Diseases and Immunity, College of Medicine, East Tennessee State University, Johnson City, TN, USA. moorman@etsu.edu. 2. Department of Medicine, Division of Infectious Diseases, College of Medicine, East Tennessee State University, Johnson City, TN, USA. moorman@etsu.edu. 3. Department of Medicine, Division of Infectious Diseases, College of Medicine, East Tennessee State University, Johnson City, TN, USA. 4. Department of Community and Behavioral Health, College of Public Health, East Tennessee State University, Johnson City, TN, USA. 5. Center for Prescription Drug Abuse Prevention and Treatment, East Tennessee State University, Johnson City, TN, USA.
Abstract
PURPOSE OF REVIEW: The purpose of this review is to address infection with HIV and hepatitis C in the Appalachian region of the USA and the driving forces underlying this epidemic. We seek to discuss epidemiology of disease and the possible interventions to reduce incidence and burden of disease in this resource-limited area. RECENT FINDINGS: The rise of the opioid crisis has fueled a rise in new hepatitis C infection, and a rise in new HIV infection is expected to follow. Injection drug use has directly contributed to the epidemic and continues to remain a risk factor. Men who have sex with men remains a significant risk factor for HIV acquisition as well. Progress has been made in the battle against HIV and, to a lesser extent, hepatitis C, but much more can be done. Limited data on co-infection with HIV/HCV are currently available for this at-risk region, but it is clear that Appalachia is highly vulnerable to co-infection outbreaks. A multipronged approach that includes advances in assessment of co-infection and education for both patients and clinicians can help to recognize, manage, and ideally prevent these illnesses.
PURPOSE OF REVIEW: The purpose of this review is to address infection with HIV and hepatitis C in the Appalachian region of the USA and the driving forces underlying this epidemic. We seek to discuss epidemiology of disease and the possible interventions to reduce incidence and burden of disease in this resource-limited area. RECENT FINDINGS: The rise of the opioid crisis has fueled a rise in new hepatitis C infection, and a rise in new HIV infection is expected to follow. Injection drug use has directly contributed to the epidemic and continues to remain a risk factor. Men who have sex with men remains a significant risk factor for HIV acquisition as well. Progress has been made in the battle against HIV and, to a lesser extent, hepatitis C, but much more can be done. Limited data on co-infection with HIV/HCV are currently available for this at-risk region, but it is clear that Appalachia is highly vulnerable to co-infection outbreaks. A multipronged approach that includes advances in assessment of co-infection and education for both patients and clinicians can help to recognize, manage, and ideally prevent these illnesses.
Authors: Andrew Kolodny; David T Courtwright; Catherine S Hwang; Peter Kreiner; John L Eadie; Thomas W Clark; G Caleb Alexander Journal: Annu Rev Public Health Date: 2015-01-12 Impact factor: 21.981
Authors: Jennifer R Havens; Michelle R Lofwall; Simon D W Frost; Carrie B Oser; Carl G Leukefeld; Richard A Crosby Journal: Am J Public Health Date: 2012-11-15 Impact factor: 9.308
Authors: Jeanne M Marrazzo; Carlos del Rio; David R Holtgrave; Myron S Cohen; Seth C Kalichman; Kenneth H Mayer; Julio S G Montaner; Darrell P Wheeler; Robert M Grant; Beatriz Grinsztejn; N Kumarasamy; Steven Shoptaw; Rochelle P Walensky; Francois Dabis; Jeremy Sugarman; Constance A Benson Journal: JAMA Date: 2014 Jul 23-30 Impact factor: 56.272
Authors: Vaishaali Natarajan; Camille R Simoneau; Ann L Erickson; Nathan L Meyers; Jody L Baron; Stewart Cooper; Todd C McDevitt; Melanie Ott Journal: Open Biol Date: 2022-03-02 Impact factor: 6.411